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Infertility affects about one in six couples attempting pregnancy, with the man responsible in approximately half of the
cases. Because the pathophysiology underlying azoospermia is not elucidated, most male infertility is diagnosed as
idiopathic. Genome-wide gene expression analyses with microarray on testis specimens from 47 non-obstructive
azoospermia (NOA) and 11 obstructive azoospermia (OA) patients were performed, and 2,611 transcripts that
preferentially included genes relevant to gametogenesis and reproduction according to Gene Ontology classification
were found to be differentially expressed. Using a set of 945 of the 2,611 transcripts without missing data, NOA was
further categorized into three classes using the non-negative matrix factorization method. Two of the three subclasses
were different from the OA group in Johnsen’s score, FSH level, and/or LH level, while there were no significant
differences between the other subclass and the OA group. In addition, the 52 genes showing high statistical difference
between NOA subclasses (p , 0.01 with Tukey’s post hoc test) were subjected to allelic association analyses to identify
genetic susceptibilities. After two rounds of screening, SNPs of the ADP-ribosyltransferase 3 gene (ART3) were
associated with NOA with highest significance with ART3-SNP25 (rs6836703; p¼0.0025) in 442 NOA patients and 475
fertile men. Haplotypes with five SNPs were constructed, and the most common haplotype was found to be under-
represented in patients (NOA 26.6% versus control 35.3%, p ¼ 0.000073). Individuals having the most common
haplotype showed an elevated level of testosterone, suggesting a protective effect of the haplotype on
spermatogenesis. Thus, genome-wide gene expression analyses were used to identify genes involved in the
pathogenesis of NOA, and ART3 was subsequently identified as a susceptibility gene for NOA. These findings clarify the
molecular pathophysiology of NOA and suggest a novel therapeutic target in the treatment of NOA.
Citation: Okada H, Tajima A, Shichiri K, Tanaka A, Tanaka K, et al. (2008) Genome-wide expression of azoospermia testes demonstrates a specific profile and implicates ART3
in genetic susceptibility. PLoS Genet 4(2) e26. doi:10.1371/journal.pgen.0040026
Introduction
Spermatogenesis, a major function of mammalian testes, is
complex and strictly regulated. While spermatogenesis is a
maturation of germ cells, other cells including Sertoli, Leydig,
and peritubular myoid cells also play important roles, and
defects at any differentiation stage might result in infertility.
Male infertility is estimated to affect about 5% of adult
human males, but 75% of the cases are diagnosed as
idiopathic because the molecular mechanisms underlying
the defects have not been elucidated. In consequence, an
estimated one in six couples experiences difﬁculty in
conceiving a child despite advances in assisted reproductive
technologies. Male-factor infertility constitutes about half of
the cases, and a signiﬁcant proportion of male infertility is
accompanied by idiopathic azoospermia or severe oligozoo-
spermia, which may well have potential genetic components.
It is well-recognized that men with very low sperm counts (,1
million/ml), identiﬁed through an infertility clinic, have a
higher incidence of Y-chromosome microdeletion (up to
17%) [1,2]. However, the genetic causalities of most cases of
azoospermia are not known.
Global gene-expression proﬁling with microarray technol-
ogies has been applied with great promise to monitor
biological phenomena and answer biological questions.
Indeed, microarray technologies have been successfully used
to identify biomarkers, disease subtypes, and mechanisms of
toxicity. We applied microarray analysis to testis specimens
from infertile individuals including patients with obstructive
azoospermia (OA) and non-obstructive azoospermia (NOA
[OMIM %606766]) to characterize NOA and to identify the
speciﬁc pathophysiology and molecular pathways of the
disease. In addition, we attempted to identify genetic
susceptibility to NOA from genes differentially expressed in
NOA testes.
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azoospermia have been surveyed in humans and mice,
especially since gene targeting technology accelerated the
identiﬁcation of genes that play crucial roles in spermato-
genesis [3]. Because spermatogenesis is a complex process
including meiosis, a germ cell–speciﬁc event, gene expression
proﬁles speciﬁc to the differentiation stage, clinically
classiﬁed by the Johnsen’s score, were examined to provide
insight into the pathogenesis of azoospermia [4]. In the
current study, we performed microarray analyses on biopsied
testes obtained from 47 NOA patients at diverse clinical
stages without prior selection and 11 OA patients. The 47
NOA samples showed a wide range of heterogeneity,
including a series of impairments at the differentiation stage
of spermatogenesis that so far have been evaluated mainly by
pathological ﬁndings. Thus, classiﬁcation of NOA at the
transcriptome level is a necessary ﬁrst step in elucidation of
the molecular pathogenesis of NOA. To do this, we adopted
the non-negative matrix factorization (NMF) method, an
unsupervised classiﬁcation algorithm developed for decom-
posing images that has been applied in various ﬁelds of
science including bioinformatics because of its potential for
providing insight into complex relationships in large data sets
[5–7]. 47 of the NOA-samples were divided into three
subclasses by the NMF method, and each class was associated
with clinical features. 149 transcripts were identiﬁed as
differentially expressed genes among the NOA subclasses
according to a statistical criterion, and the features involved
in spermatogenesis based on Gene Ontology classiﬁcation
were demonstrated.
The genetic causality of NOA most likely involves the
expression level of a susceptibility gene, which might be
detected by genome-wide gene expression analysis. While it is
daunting to identify genetic susceptibility from 100-1000
differentially expressed genes, genetic susceptibility might
more readily be identiﬁed from random genes differentially
expressed with high signiﬁcance rather than by investigating
only genes in a speciﬁc biological pathway. Based on a well-
deﬁned statistical procedure, 52 candidate genes for NOA
were catalogued by gene expression proﬁle and screened for
allelic association study in a total of 442 NOA patients and
475 fertile male controls. After gene-centric selection of
SNPs, 191 SNPs of 42 candidate genes were initially evaluated
for allelic association with NOA. After two rounds of
screening, SNPs of the ADP-ribosyltransferase 3 (ART3) gene
were found to be signiﬁcantly associated with NOA, and ﬁve
of these SNPs were selected for haplotype construction. The
most common haplotype was signiﬁcantly under-represented
in the patients and may be protective. The functional impact
of this haplotype was further investigated.
Results
Extraction of NOA-Related Gene Expression Profile
As shown in Figure 1A, the most notable difference in
histological ﬁndings between NOA and OA testes was that the
NOA patients exhibited, at varying degrees, incomplete sets
of spermatogenic germ cells (spermatogonia, spermatocytes,
spermatids, and spermatozoa) in the seminiferous tubules. In
severe NOA patients, we could not even detect Sertoli cells,
the major somatic cells of the seminiferous tubules, on
histological examination (ﬁgure not shown), indicating
clinical heterogeneity of NOA testes. In order to elucidate
the molecular systems underlying NOA at the transcriptome
level, it is important to extract genes reﬂecting the diversity
of NOA phenotypes. For this purpose, we ﬁrst compared
global gene expression proﬁles in NOA testes to those of OA
testes using the Agilent Human 1A(v2) Oligo Microarray
system. We chose the ‘standard reference design’ in two-color
microarray experiments as an experimental design for the
expression analysis [8], where a single microarray was used to
compare either NOA or OA to the testicular reference RNA
as described in Materials and Methods (Figure 1B).
Of the 18,716 transcripts screened with the microarray, we
obtained transcripts that showed a 2-fold mean expression
difference between NOA and the reference, the NOA group;
the OA group comprised transcripts showing less than 2-fold
mean expression difference between OA and the reference
(Figure 1B). Of the transcripts overlapping the two groups,
2,611 transcripts were found to be differentially expressed
between NOA and OA testes after statistical ﬁltering (based
on lowess-normalized natural log[Cy5/Cy3], Bonferroni’s
corrected p , 0.05). This gene list, termed NOA-related
target genes, comprised 902 elevated and 1,709 decreased
transcripts in NOA testes. To characterize the gene list from
the biological aspect, the 2,611 transcripts were subjected to
functional clustering according to Gene Ontology (GO)
classiﬁcation for biological processes with GeneSpring soft-
ware. We identiﬁed a total of 190 GO categories that were
signiﬁcantly (p , 0.05 without multiple testing correction)
over-represented among the 2,611 transcripts. Table 1 shows
the ten top-ranked GO categories in descending order of
signiﬁcance based on p-values with Fisher’s exact test. It is
notable that the GO categories involved in gametogenesis
(GO:48232; 7283; 7276), reproduction (GO:19953; 3), and the
cell cycle (GO:279; 51301; 7049; 7067) are signiﬁcantly
associated with the gene list. We further analyzed two
separate subsets comprising 1,709 decreased (Figure 2, upper)
and 902 elevated (Figure 2, lower) transcripts, based on their
GO annotations. The top-ranked GO categories for NOA-
related target genes are more similar to those of the 1,709
decreased transcripts than to those of the 902 elevated ones
(Figure 2; Table 1). Thus, the predominant features may
reﬂect spermatogenic defects common to NOA testes. On the
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Author Summary
Worldwide, approximately 15% of couples attempting pregnancy
meet with failure. Male factors are thought to be responsible in
20%–50% of all infertility cases. Azoospermia, the absence of sperm
in the ejaculate due to defects in its production or delivery is
common in male infertility. In this study, we focused on non-
obstructive azoospermia (NOA) because the etiologies of obstruc-
tive azoospermia are well studied and distinct from those of NOA.
Microdeletions of the Y chromosome are thus far the only genetic
defects known to affect human spermatogenesis, but most cases of
NOA are unsolved. Because NOA results from a variety of defects in
the developmental stages of spermatogenesis, the stage-specific
expressions of genes in the testes must be investigated. Thus,
genome-wide gene expression analyses of testes of NOA can
provide insight into the several etiologies and genetic susceptibil-
ities of NOA. In the present study, we analyzed several differentially
expressed genes in NOA subclasses and identified ART3 as a
susceptibility gene for NOA.other hand, 902 transcripts elevated in NOA testes exhibited
a distinct GO proﬁle that included several GO categories
involved in biosynthesis and metabolism in cytoplasm (Figure
2), implying an increase in cytoplasmic turnover rates such as
steroid turnover in NOA testes.
Discovery of Three Molecular Subclasses of NOA Testes
To clarify heterogeneity of NOA testes at the transcrip-
tome level, we further examined NOA-related target genes to
identify NOA subclasses without prior classiﬁcation with
pathological features. We adopted the NMF algorithm
coupled with a model selection method [6] to a complete
dataset of 945 out of the 2,611 transcripts without missing
values of signal intensities for a total of 47 NOA samples.
Figure 3A shows reordered consensus matrices averaging 50
connective matrices generated for subclasses K ¼ 2, 3, 4, and
5. Distinct patterns of block partitioning were observed at
models with 2 and 3 subclasses (K ¼ 2 and 3), whereas higher
ranks (K ¼ 4 and 5) made block partitioning indistinct. Thus,
the NMF method predicts the existence of reproducible and
robust subclasses of NOA samples for K ¼ 2 and 3. This
prediction was quantitatively supported by higher values of
cophenetic correlation coefﬁcients (coph) for NMF-clustered
matrices. The NMF class assignment for K ¼ 3 showed the
highest coph value (coph ¼ 0.993), indicating that three
molecular subclasses, termed NOA1, NOA2, and NOA3, are
Table 1. Top-Ranked Ten Categories of Gene Ontology
Significantly Overrepresented among 2,611 Transcripts
GO Category
a Genes within GO
Category
 logP
c
Number Percent
b
Male gamete generation (GO:48232) 55 3.1 12.0
Spermatogenesis (GO:7283) 55 3.1 12.0
Sexual reproduction (GO:19953) 70 3.9 11.2
Gametogenesis (GO:7276) 59 3.3 10.5
Reproduction (GO:3) 75 4.2 8.3
M phase (GO:279) 57 3.2 6.7
Microtubule-based process (GO:7017) 42 2.4 6.5
Cell division (GO:51301) 48 2.7 6.5
Cell cycle (GO:7049) 144 8.1 6.4
Mitosis (GO:7067) 45 2.5 5.6
aAll GO categories are from the subontology biological process.
bPercent denotes the percentage of coverage of NOA-related target genes. Of the 2,611
transcripts in the gene list, 1,784 are used for calculating the percentage of genes with a
given GO annotation because the GO annotations regarding biological process for the
others are not available.
cp-Value was determined by Fisher’s exact test, comparing the observed percentage of
NOA-related target genes with a given GO annotation to that of genes on the Agilent
Human 1A(v2) microarray with the same GO annotation.
doi:10.1371/journal.pgen.0040026.t001
Figure 1. Experimental Design to Extract NOA-related Target Genes
(A) Representative testicular biopsies from NOA (left panel) and OA (right panel) patients. The seminiferous tubules in NOA testis show Sertoli cells only;
testicular histology of the OA patient indicates the presence of germ cells at all stages of spermatogenesis.
(B) Strategy for discovering the NOA-specific expression profile, i.e., the NOA-related target genes. Compared with the expression level of reference
RNA, the NOA group, with expression undergoing 2-fold or more mean change, was extracted; the OA group comprised transcripts with less than 2-fold
mean expression change. Of the overlapping transcripts, only those with statistically significant difference between NOA and OA (p , 0.05 with
Bonferroni’s correction) were identified as differentially expressed.
doi:10.1371/journal.pgen.0040026.g001
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samples. For comparative analysis of class discovery, a
hierarchical clustering (HC) approach was applied to log-
transformed normalized ratios for NOA-related target genes.
As shown in Figure 3B, the HC dendrogram exhibited a
clustering pattern similar to that of the NMF-based sub-
classiﬁcation, as the three NMF-subclasses of NOA samples
tended to form distinct clusters in the HC analysis. Thus, the
HC clustering for NOA-related target genes appears to justify
the three NMF-based subclasses of NOA samples.
To investigate the clinical features of the three NOA
subclasses, we compared several clinical measures among the
subclasses. The results obtained from statistical analyses in a
total of four groups including the OA group are summarized
in Table 2. We found signiﬁcant differences in the three NOA-
related clinical characteristics, testicular histological score
(Johnsen’s score, p ¼ 1.4 3 10
 6), serum FSH level (p ¼ 9.8 3
10
 4), and LH level (p ¼ 0.0051) among the four groups using
Kruskal-Wallis test, but there were no differences in age and
serum testosterone level. Post hoc pairwise comparisons
revealed that both the NOA1 and NOA2 groups exhibited
low Johnsen’s scores and high levels of serum FSH compared
with the OA group (Table 2). In the NOA1 group, a high LH
level (p , 0.01) also was found compared with the OA group.
On the other hand, there were no signiﬁcant differences in any
of the parameters between the NOA3 and OA groups, as well
as among three NOA subclasses in post hoc analysis. Elevations
of serum FSH and LH concentrations often are observed in
infertile patients with abnormal testicular histologies and are
correlated, to some extent, with the severity of spermatogenic
defects [9,10]. Testicular histologies of NOA and OA patients
have been evaluated by the Johnsen’s scores, ranging from 10
to 1 according to the presence or absence of spermatogenesis-
related cell types (spermatozoa, spermatids, spermatocytes,
spermatogonia, and Sertoli cells) in seminiferous tubules [11].
The NMF-based subclasses of testicular gene expression
showed that the low score classes had heterogeneity (NOA1
and NOA2), presumably indicating the possibility of distinct
spermatogenic defects at the molecular level that could not be
detected by morphological examination.
Identification of Transcripts Differentially Expressed in the
Three NOA Subclasses
Based on the three NOA subclasses, we conducted further
statistical analyses to extract transcripts representing ex-
pression differences between NOA subclasses from the NOA-
related target genes (Figure S1). 149 out of 2,611 transcripts
showed signiﬁcant differences (p , 0.05, Tukey’s post hoc test)
in testicular expression between the NOA subclasses, as
summarized in Table S1. To characterize this gene list based
on GO classiﬁcation for biological processes, we examined
which GO terms were highly associated with the 149 differ-
entially expressed transcripts, relative to those for the NOA-
related gene list (as shown in Table 1 and Figure 2). Figure 4
shows the 10 top-ranked GO categories for the 149 tran-
scripts, using the 2,611 NOA-related target transcripts as a
background set of genes for this GO analysis. Nine GO
categories excluding gametogenesis appeared to be novel,
indicating that highly signiﬁcant enrichments of transcripts
involved in DNA metabolism (GO:6259; 6325; 6323; 6281),
Figure 2. Comparison of Ten Top-ranked Gene Ontology (GO) Categories Significantly Over-Represented in the Two Subsets (1,709 Decreased, Upper
Panel; 903 Elevated, Lower Panel) of NOA-related Target Genes
Blue and red bars represent p-values for the ten top-ranked GO categories over-represented in the decreased and elevated gene lists, respectively. Black
bars show the corresponding p-value using 2,611 NOA-related target genes. p-Values were determined by Fisher’s exact test using all of the GO-
annotated genes on the Agilent Human 1A(v2) microarray as a background, as shown in Table 1. The p-values are expressed as the negative logarithm
(base 10).
doi:10.1371/journal.pgen.0040026.g002
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ART3 Genetic Susceptibility Gene for NOAchromosome organization and biogenesis (GO:51276; 7001),
sex differentiation (GO: 7548), and response to endogenous
stimulus (GO:9719; 6974) occurred after the extraction of 149
transcripts from the NOA-related target gene list (Figure 4).
Other features of the 149 transcripts from the gene list (Table
S1) were as follows: (1) a high frequency (24.2%) of sex
chromosome-linked genes; (2) a high frequency (13.4%) of
genes encoding cancer/testis antigens [12,13]; and (3) a
moderate frequency (6.7%) of male infertility-related genes.
Defect of these genes results in male infertility/subfertility in
mice [3,14–16].
Twenty-ﬁve of the 149 transcripts showing differences in
between-subclass expression displayed elevated expression in
NOA, while the others (124 transcripts) had decreased
expression (Table S1). The 25 NOA-elevated transcripts
accounted only for differences in testicular expression
between NOA1 and the other two subclasses, NOA2 and
NOA3 (Figure S2; Table S1), suggesting testicular hyper-
activity in NOA1 patients. For example, 3b-hydroxysteroid
dehydrogenase, encoded by HSD3B2 and HSD3B1, plays a
crucial role in biosynthesis of testosterone in Leydig cells [17].
Expression levels of the two transcripts in the NOA1 subclass
were higher than those in the NOA2 and NOA3 subclasses,
and the expression difference between NOA1 and NOA3 was
signiﬁcant by Tukey’s post hoc test (Figure S2; Table S1). As the
NOA1 subclass showed signiﬁcantly high LH and slightly low
testosterone levels (Table 2), the elevated levels of the two
transcripts may be explained by a compensation process for
maintaining normal testosterone level. Thus, such enhanced
steroidogenesis of the NOA1 subclass might favor, even if
only slightly, testicular hyperactivity in NOA1 patients.
On the other hand, among the 124 NOA-decreased
transcripts, most transcripts (118/124) showed expression
differences between NOA3 and the other two subclasses
(Figures S2–S4; Table S1). Expression levels of these tran-
scripts in the NOA3 subclass were similar to those in testis
reference RNA (Figures S2–S4), indicating that the NOA3
subclass has a mild defect in spermatogenesis. This notion is
supported by the fact that the expression of INHBB encoding
inhibin b subunit B in the NOA3 subclass is normal while
NOA1 and NOA2 subclasses showed low levels, indicating
that inhibin b may be a marker of testicular dysfunction, as
previously reported [18].
Verification of Between-Subclass Differences in Testicular
Expression by Quantitative Real-Time RT-PCR
To evaluate the appropriateness of microarray data on
transcripts representing expression differences between
NOA subclasses, we selected 53 with high signiﬁcance (p ,
0.01, Tukey’s post hoc test, Figure S1 and Table S1) out of the
149 differentially expressed transcripts and subjected them to
real-time RT-PCR analysis. Of the 53 transcripts, the highly
Figure 3. Non-Negative Matrix Factorization (NMF) and Hierarchical Clustering (HC)-based Subclassification of 47 NOA Samples
(A) Reordered consensus matrices averaging 50 connectivity matrices computed at K¼2–5 (as the number of subclasses modeled) for the NOA data set
comprising of NOA-related target genes. NMF computation and model selection were performed according to Brunet et al. [6] as described in Materials
and Methods. According to cophenetic correlation coefficients (coph) for NMF-clustered matrices, the NMF class assignment for K ¼ 3 was the most
robust.
(B) The HC method incorporated in GeneSpring also was used to classify NOA heterogeneity in testicular gene expression. To display correspondences
of subclassification by the two methods, the NMF class assignments for K ¼ 3 are shown color-coded; NOA1 (green), NOA2 (pink), and NOA3 (light
purple).
doi:10.1371/journal.pgen.0040026.g003
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detected with non-speciﬁc assay as a mixture of transcripts.
Thus, 50 genes and one gene mixture were subjected to real-
time RT-PCR. As shown in Figure S5, real-time RT-PCR data
of the 51 transcripts were highly correlated with the results of
microarray analysis, the squares of correlation coefﬁcients
(R
2) ranging from 0.40 (CT45–2) to 0.90 (GAJ). This validation
analysis also provided statistically positive evidence on
between-subclass differences for all of the 51 transcripts (p
, 0.05 with Kruskal-Wallis test, data not shown).
Screening of Candidate Genes for Genetic Susceptibility
for NOA
One approach to prioritizing candidate genes for genetic
susceptibility underlying NOA is to adopt gene expression
data from NOA tissues. Genes that show differences in
expression level between NOA subclasses regardless of
biological impact were selected based on the concept that
polymorphic variation in gene expression among unrelated
individuals is largely due to polymorphisms in DNA sequence
[19,20]. 52 genes having statistical differences in expression (p
, 0.01, Table S1) were regarded as candidates for allelic
association with NOA. Despite the fact that these genes were
not selected based on pathological relevance to NOA, genes
such as SYCP3, DAZL, and INHBB, which were reported to
function in spermatogenesis were included [21–23]. 191 single
nucleotide polymorphisms (SNPs) of 42 genes were subjected
to allelic association study with 190 NOA patients and 190
fertile men in the ﬁrst round of screening. Ten genes
Figure 4. Significant Enrichments of Gene Ontology Categories in GO-based Profiling of 149 Differentially Expressed Transcripts
Grey bars represent p-values (expressed as the negative logarithm [base 10]) for the 10 top-ranked GO categories over-represented in the 149
differentially expressed transcripts, using the 2,611 NOA-related target transcripts as a background set of genes for the determination of p-values. The
actual number of differentially expressed transcripts involved in each category is given in parentheses. In the process of extracting the 149 transcripts
from the NOA-related target gene list, sets of genes involved in nine GO categories, marked in magenta, were more condensed because they were not
found in the previous 10 top-ranked GO lists of NOA-related target genes (see Table 1 and Figure 2).
doi:10.1371/journal.pgen.0040026.g004
Table 2. Clinical Characteristics of Three Molecular Subclasses of NOA
Group n Age
(Years)
Range Johnsen’s
Score*
Range Serum FSH
(mIU/ml)*
Range Serum LH
(mIU/ml)*
Range Serum T
(ng/ml)
Range
OA 11 33.3 6 8.5 25–57 7.9 6 1.2 5.1–9 10.1 6 9.3 3.6–31.4 4.5 6 2.3 1.3–9.3 4.8 6 1.7 3.4–7.0
NOA1 13 37.5 6 6.0 27–52 2.0 6 1.0
a 1–4 34.5 6 11.5
a 19.0–53.3 13.6 6 6.0
a 5.2–20.8 2.8 6 1.0 1.4–4.7
NOA2 27 34.4 6 5.6 24–46 2.2 6 1.1
b 1–6 28.3 6 6.4
c 19.0–39.3 7.2 6 2.6 2.4–13.0 3.7 6 1.4 2.2–5.8
NOA3 7 33.0 6 4.8 26–40 4.0 6 1.6 2–6.5 22.7 6 8.8 12.6–28.6 5.9 6 0.9 5.3–7.0 4.3 6 2.7 2.0–7.3
The data are represented as mean 6 standard deviation.
*p , 0.01 (Kruskal-Wallis test between four groups).
ap , 0.01, NOA1 versus OA (Scheffe’s posthoc test on Johnsen’s score, FSH and LH between four groups).
bp , 0.01, NOA2 versus OA (Scheffe’s posthoc test on Johnsen’s score, FSH and LH between four groups).
cp , 0.05, NOA2 versus OA (Scheffe’s posthoc test on Johnsen’s score, FSH and LH between four groups).
FSH, follicle-stimulating hormone; LH, luteinizing hormone; T, testosterone.
doi:10.1371/journal.pgen.0040026.t002
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ART3 Genetic Susceptibility Gene for NOA(CTAG1B, LOC158812, LOC255313, MAGEA2, PEPP-2, TSPY1,
TSPY2, VCX3A, VCY, and XAGE1) were not analyzed because
no gene-based SNPs with minor allele frequency (MAF) .
0.05 could be found. We identiﬁed seven genes (ART3,
LOC92196, NYD-SP20, PAGE5, TEX14, TKTL1, and XAGE5)
with at least one SNP showing a discrepancy in MAF of 5% or
greater between cases and controls (Table S2). Forty-four
SNPs in the seven genes were subjected to a second round of
screening by increasing sample size (380 NOA patients and
380 fertile men). After the two rounds of screenings, only one
SNP (rs6836703) of ART3 (ADP-ribosyltransferase 3) was
positively associated with NOA after Bonferroni’s correction
for multiple testing (Table 3; v
2 ¼ 11.7, corrected p ¼ 0.027).
Allelic Association Study with ART3
We focused on ART3 based on the result of the two rounds
of screenings, and identiﬁed 38 SNPs with MAF . 0.1 by
database search or direct sequencing of the gene. 442 NOA
patients (cases) and 475 fertile men (controls) were geno-
typed. Because we intended in this study to ﬁnd a common
genetic cause for NOA, patients with microdeletions of the Y
chromosome at the azoospermia factor (AZF) locus, one of
the major causes of NOA [1,2], were not excluded from the
cases. However, to characterize the cases in regard to the AZF
deletions, we examined the incidence of the deletions in a
subset of the cases. Of the 442 NOA patients, 99 were
examined by PCR-based screening. Fourteen (14.1 %) of the
Table 3. Analyses of Allelic Association between 44 SNPs of Seven Candidate Genes and Japanese NOA in Second Round of Initial
Screening (380 Cases versus 380 Controls)
Gene Map rs ID Sequence Position
a Localization Variation MAF v
2 Nominal p
Case Control
ART3 4q21.1 rs9995300  2520 59-upstream A/G 40.7% 34.6% 5.60 0.018
rs17001357 12048 Intron3 C/T 41.5% 46.4% 3.50 0.061
rs11097230 19801 Intron3 A/G 32.9% 40.1% 7.79 0.0053
rs6836703 34283 Intron11 G/A 41.4% 32.8% 11.7 0.00061*
rs1128864 37726 Exon12-Non-synonymous T/C 39.3% 33.2% 5.53 0.019
rs6840007 43329 39-downstream A/T 34.5% 28.4% 6.16 0.013
LOC92196 2q24.1 rs4254463  5901 59-upstream G/A 18.1% 16.7% 0.46 0.50
rs908404 2538 Intron1 T/C 17.9% 16.1% 0.69 0.41
rs9869 11757 Exon3-non-synonymous C/T 19.7% 14.8% 5.85 0.016
rs10016 20600 39-UTR G/A 9.8% 10.0% 0.00 0.99
NYD-SP20 17p13.3 rs3829957  3785 59-upstream C/T 36.0% 36.2% 0.00 0.99
rs2318035 12022 Intron5 A/G 36.9% 36.1% 0.09 0.77
rs1488689 22797 Exon6-non-synonymous A/G 34.8% 34.5% 0.01 0.94
rs17822627 31572 Exon9-synonymous T/C 35.6% 34.3% 0.23 0.63
rs2318033 40646 39-downstream A/T 37.3% 36.4% 0.10 0.75
PAGE5 Xp11.21 rs2148982 2260 Intron3 G/A 30.9% 30.2% 0.01 0.92
rs5913800 5332 39-downstream A/G 31.0% 29.8% 0.06 0.81
rs5914276 8924 39-downstream C/G 31.4% 29.0% 0.40 0.53
rs11091394 14424 39-downstream A/G 32.4% 28.2% 1.15 0.28
TEX14 17q22 rs686425  7314 59-upstream G/A 47.1% 47.3% 0.00 0.99
rs302874 1420 Intron1 C/T 47.3% 47.2% 0.00 0.99
rs302865 12439 Intron1 C/T 46.7% 46.3% 0.01 0.93
rs446613 19870 Intron1 A/C 47.6% 49.1% 0.27 0.60
rs1631237 34721 Intron2 C/T 46.6% 47.3% 0.05 0.82
rs302843 41430 Intron2 A/G 46.1% 49.0% 0.87 0.35
rs2611782 51460 Intron2 C/T 47.5% 47.3% 0.00 0.99
rs591200 63515 Intron2 C/T 42.8% 41.3% 0.25 0.62
rs9898626 71197 Intron5 G/C 47.1% 46.4% 0.04 0.85
rs302854 85804 Intron10 T/C 47.0% 48.0% 0.10 0.75
rs8072873 100367 Intron15 G/C 24.6% 26.0% 0.30 0.58
rs6503870 110398 Exon20-non-synonymous T/C 46.8% 47.0% 0.00 0.95
rs1267542 114726 Intron22 T/C 45.9% 49.1% 0.94 0.33
rs3803751 119060 Intron24 T/C 23.5% 25.3% 0.61 0.43
rs1267545 122507 Intron26 G/A 46.0% 48.1% 0.47 0.49
rs1974586 128685 Intron29 C/T 23.5% 26.6% 1.67 0.20
rs2333332 138362 39-downstream T/C 48.4% 49.0% 0.04 0.85
rs714959 140815 39-downstream T/C 23.6% 22.6% 0.17 0.68
rs12453459 145125 39-downstream C/T 49.0% 45.6% 0.90 0.34
TKTL1 Xq28 rs631  8147 59-upstream G/A 23.4% 18.5% 2.37 0.12
rs6655282 12986 Intron6 G/A 10.7% 6.8% 3.17 0.075
rs766420 20834 Intron9 C/G 23.7% 22.7% 0.05 0.82
rs2872817 24848 39-UTR A/G 28.5% 26.8% 0.18 0.67
rs5945413 30181 39-downstream A/T 27.2% 27.0% 0.00 0.99
XAGE5 Xp11.22 rs4543711 5279 Intron4 A/G 4.9% 7.9% 2.30 0.13
aNucleotide position from the first nucleotide of exon 1 of each gene.
*Statistically significant (corrected p ¼ 0.027) based on Bonferroni-corrected p-value.
doi:10.1371/journal.pgen.0040026.t003
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ART3 Genetic Susceptibility Gene for NOA99 cases examined showed the AZF deletions, and NOA
patients with AZFc deletions were most frequent among the
14 cases (data not shown). The overall deletion frequency was
comparable to those of other studies [1,2], in which the higher
incidence of AZFc deletions also was observed. The clinical
characteristics of patients with the AZF deletions did not
differ from those of the other NOA patients (data not shown).
Linkage disequilibrium map showed that all of the SNPs of
ART3 were in near complete LD evaluated with D’ statistic
(jD’j . 0.7) in both cases and controls (only controls are
displayed in Figure 5). None of the SNPs in the controls
showed deviation from Hardy-Weinberg’s equilibrium at a
threshold of p , 0.01 (data not shown). As shown in Table 4,
SNPs showing positive associations based on nominal p-values
were widely distributed throughout ART3. The most signiﬁ-
cant association was observed with ART3-SNP25 (rs6836703)
located in intron 11 of ART3 (v
2 ¼ 9.16, nominal p ¼ 0.0025,
odds ratio [95% CI] ¼ 1.34 [1.11–1.63]). We applied the
permutation method for adjustment of multiple testing to
avoid a false positive result [24]. A total of four SNPs
including ART3-SNP25 met the empirical signiﬁcance level of
p , 0.05 (Table 4).
For the haplotype-based association study, we ﬁrst selected
ﬁve SNPs (ART3-SNP1, 5, 23, 25, and 28) as tag SNPs captured
through LD in ART3 from 15 SNPs with nominal p , 0.05 at a
threshold of r
2   0.8 with Tagger software [25]. Haplotype
frequencies were inferred using an expectation-maximization
(EM) algorithm. After excluding rare haplotypes (frequency ,
0.01), association of ART3 haplotypes with NOA was
examined in 442 cases and 475 controls. Haplotype H1, the
most common haplotype in controls, was under-represented
in cases with signiﬁcance (Figure 6; 26.6% in cases and 35.3 %
in controls; v
2 ¼ 15.7, df ¼ 1, nominal p ¼ 0.000073),
indicating a protective impact of haplotype H1. After
Bonferroni’s correction for multiple testing, a protective
effect of haplotype H1 was still signiﬁcant (corrected p ¼
0.00080). Other haplotypes showed no signiﬁcant difference
in frequencies between cases and controls (Figure 6). We also
applied a Bayesian algorithm for phasing haplotypes with
PHASE version 2.1.1 [26,27]. Regardless of haplotype-phasing
methods, haplotype H1 was the most frequent in controls
(26.4% in cases and 35.0% in controls), and a signiﬁcant
difference in haplotype H1 frequency between cases and
controls was observed (permutation p , 0.0001 in global
comparison, generated after 10,000 iterations).
Clinical Relevance of the Haplotype Associations
The functional relevance of haplotype H1 in comparison
with the clinical data was then explored. Diplotype was
Figure 5. Linkage Disequilibrium Pattern of ART3
The gene structure together with the position of 38 SNPs is shown. Pairwise LD coefficients, D’ and r
2, of controls were determined and expressed as a
block structure. In the schematic block, red boxes indicate pairwise LD of jD’j . 0.9 or r
2 . 0.8 and pink boxes 0.9  j D’j . 0.7 or 0.8   r
2 . 0.5. Blank
boxes represent jD’j 0.7 or r
2   0.5.
doi:10.1371/journal.pgen.0040026.g005
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ART3 Genetic Susceptibility Gene for NOAinferred with EM algorithm, and three categories (code 0, 1,
and 2) were deﬁned by the number of haplotype H1 carried
without counting the other haplotypes, and nonparametric
analysis of variance test with clinical data was performed.
Serum levels of hormones (LH, FSH, and testosterone),
other biochemical and pathophysiological markers, and
Johnsen’s score were analyzed by Kruskal-Wallis test with a
Bonferroni/Dunn post hoc test between the three diplo-
groups. Serum testosterone levels were signiﬁcantly differ-
ent among the three groups (Figure 7; df¼2, p¼0.0093), but
there were no signiﬁcant differences in other clinical
markers. Post hoc pairwise comparisons revealed that serum
testosterone levels were signiﬁcantly higher in the subgroup
having two copies of haplotype H1 than in a subgroup with
one or no haplotype H1 (p ¼ 0.0064 or p ¼ 0.0004,
respectively, Figure 7). PHASE-inferred individual diplo-
types also revealed a similar correlation between diplo-
groups of haplotype H1 and serum testosterone levels (data
not shown).
ART3 Protein Localization in Azoospermic Testis
ART3 protein expression in azoospermic testes was
examined by immunohistochemical analysis. As shown in
Figure 8, speciﬁc staining of ART3 protein was predom-
inantly observed in spermatocytes in OA testes (Figure 8C–
8E) as well as in normal testes from individuals of accidental
sudden-death (Figure 8A and 8B). Staining was not observed
in other stages of undifferentiated germ cells or Sertoli cells
in the seminiferous tubules, or the interstitial tissues such as
Leydig cells. On the other hand, we did not detect any ART3
protein in NOA testes with Johnsen’s scores ranging from 2 to
3, which showed no spermatocytes, spermatids, or spermato-
zoa in the seminiferous tubules (n ¼ 12 samples; Figure 8F–
8H). There was no marked difference in testicular ART3
Table 4. Allelic Association of 38 SNPs in ART3 with NOA in Japanese Population (442 NOA Patients versus 475 Controls)
Number rs ID Sequence Position
a Localization Variation MAF v
2 Nominal p Permutation p
b
Case Control
ART3–1 rs13111494  10376 59-upstream T/C 37.7% 43.4% 3.96 0.047 0.36
ART3–2 rs9995300  2520 59-upstream A/G 38.7% 35.8% 1.66 0.20 0.81
ART3–3 rs4859609 3333 intron2 A/G 39.3% 43.2% 2.84 0.092 0.55
ART3–4 rs7666159 3941 intron2 T/C 51.5% 48.7% 1.40 0.24 0.87
ART3–5 rs4859611 5562 intron2 T/C 43.9% 48.8% 4.42 0.035 0.29
ART3–6 rs10007524 7070 intron2 G/A 34.6% 30.7% 3.14 0.077 0.49
ART3–7 rs4859612 9950 intron3 T/G 16.8% 17.8% 0.29 0.59 1
ART3–8 rs17001357 12048 intron3 C/T 40.6% 45.9% 5.13 0.024 0.22
ART3–9 rs4308383 12986 intron3 C/T 35.8% 31.2% 4.24 0.040 0.32
ART3–10 rs17001364 13478 intron3 T/C 36.4% 31.2% 5.47 0.019 0.19
ART3–11 rs7675618 15549 intron3 G/A 35.0% 30.3% 4.33 0.038 0.31
ART3–12 rs4859422 16736 intron3 G/A 23.2% 25.1% 0.88 0.35 0.96
ART3–13 rs4859614 17327 intron3 G/A 32.8% 31.2% 0.51 0.48 1
ART3–14 rs11097230 19801 intron3 A/G 32.5% 39.3% 8.73 0.0031 0.040
ART3–15 rs6829592 23717 intron4 G/A 43.3% 46.0% 1.32 0.25 0.89
ART3–16 rs13131187 25213 intron5 A/G 42.3% 45.1% 1.46 0.23 0.86
ART3–17 rs17001385 26422 intron8 C/G 32.5% 39.2% 8.84 0.0030 0.038
ART3–18 rs12331871 27635 intron8 T/G 39.7% 43.5% 2.57 0.11 0.61
ART3–19 rs17001390 28316 intron8 C/T 34.3% 30.2% 3.49 0.062 0.43
ART3–20 rs12510869 28670 intron8 A/G 23.2% 24.4% 0.36 0.55 1
ART3–21 rs13130116 29976 intron10 C/T 22.6% 24.9% 1.28 0.26 0.90
ART3–22 rs9307076 31256 intron10 G/A 40.3% 43.5% 1.92 0.17 0.75
ART3–23 rs4599438 32278 intron10 A/G 37.5% 31.7% 6.71 0.010 0.11
ART3–24 rs17001409 33549 intron11 T/C 23.8% 25.1% 0.39 0.53 1
ART3–25 rs6836703 34283 intron11 G/A 41.2% 34.3% 9.16 0.0025 0.034
ART3–26 rs4241584 35127 intron11 C/T 30.3% 29.5% 0.13 0.72 1
ART3–27 rs4859423 35158 intron11 T/C 23.7% 25.3% 0.67 0.41 0.99
ART3–28 rs4241586 35506 intron11 T/C 39.7% 44.5% 4.14 0.042 0.33
ART3–29 rs17001416 35935 intron11 G/T 21.6% 22.5% 0.20 0.66 1
ART3–30 rs1128864 37726 exon12-non-synonymous T/C 38.2% 33.8% 3.72 0.054 0.39
ART3–31 New 37857 exon12–39-UTR G/A 34.1% 29.4% 4.58 0.032 0.28
ART3–32 rs14773 37861 exon12–39-UTR A/C 45.0% 38.1% 8.96 0.0028 0.036
ART3–33 rs7689378 38491 39-downstream A/G 21.7% 23.4% 0.67 0.41 0.99
ART3–34 rs13141802 38730 39-downstream G/C 22.3% 24.2% 0.86 0.35 0.97
ART3–35 rs10654 40031 39-downstream T/A 34.8% 30.5% 3.64 0.056 0.41
ART3–36 rs7675107 41918 39-downstream A/G 33.6% 29.1% 4.19 0.041 0.32
ART3–37 rs6840007 43329 39-downstream A/T 34.3% 29.7% 4.42 0.036 0.30
ART3–38 rs4538520 49092 39-downstream C/T 33.1% 31.7% 0.39 0.53 1
SNPs in bold show statistical significance and are subjected to haplotype analysis as shown in Figure 6.
aNucleotide position from the first nucleotide of exon 1.
bPermutation p-values generated by 10,000 iterations. SNPs in bold show statistical significance based on the permutation p-values.
doi:10.1371/journal.pgen.0040026.t004
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ART3 Genetic Susceptibility Gene for NOAprotein expression among the three ART3 diplo-groups
carrying none, one, or two copies of haplotype H1.
Discussion
Genomic Analysis of NOA
Our investigation was designed to clarify the pathogenesis
of NOA using global gene expression analyses of testis
samples from NOA patients and to identify genetic suscepti-
bilities underlying NOA from the genes differentially ex-
pressed. Large families with multiple generations having
NOA cannot be expected due to the nature of infertility, so
linkage study is impractical for NOA and has not been
reported. Alternatively, allelic association study is a practical
approach to identiﬁcation of genetic susceptibility under-
lying NOA. Thus far, more than 80 genes have been identiﬁed
as essential for male infertility in humans and mice [3]. Genes
on the Y chromosome were emphasized because of observed
microdeletions in patients, and genes such as DAZ and HSFY
were examined for possible susceptibility genes [28,29].
Recently, homozygous mutation of the aurora kinase C gene
was identiﬁed in large-headed multiﬂagellar polyploid sper-
matozoa, a rare form of infertility, using homozygosity
mapping [30]. In the current study, we applied a novel
approach to identify common susceptibility genes for NOA
by applying global gene expression analysis of NOA testes.
Based on the hypothesis that a common variant of a
susceptibility gene has resulted in altered expression in
tissues relevant to disease etiology [31], we ﬁrst elucidated the
gene expression proﬁle in testes of NOA patients and
characterized the genetic pathways that were either under-
expressed or over-expressed. Because spermatogenesis is a
complex differentiation process, NOA could result from a
defect at any stage of the process. Thus, gene expression
proﬁling of NOA tissues might well be confounded by the
difﬁculty of discerning the differential stage and the
pathological status. Feig et al. [4] examined stage-speciﬁc
gene expression proﬁles in human NOA patients after
classiﬁcation on the basis of Johnsen’s score. The testis tissues
were classiﬁed into four groups showing Sertoli-cell only
syndrome, meiotic arrest, testicular hypospermia, and testic-
ular normospermia, corresponding to Johnsen’s score 2, 5, 8,
and 10, respectively, and stage-speciﬁc differential gene
expression was monitored. We sought to identify suscepti-
bility genes underlying NOA that could affect any stage of
spermatogenesis. Testis samples subgrouped according to
Johnsen’s score in advance might identify genes affecting
multiple stages of spermatogenesis. Therefore, we globally
subgrouped the samples at diverse stages of differentiation
using an NMF method for reducing multidimensionality that
is appropriate for application to high dimensional biological
data. The NMF method subgrouped three classes, NOA1,
NOA2, and NOA3, which also were unequivocally subgrouped
by the HC approach (Figure 3). Notably, NOA1 and NOA2
represent a pathologically similar type showing low Johnsen’s
score, but were subclassiﬁed because of their distinct gene
expression pattern. NOA1 and NOA2 showed differences in
LH, FSH, and testosterone levels, thus establishing mean-
ingful biological signiﬁcance of the sub-classes (Table 2).
Genetic Susceptibility to NOA
In the current study, we adopted a novel approach to select
candidate susceptibility genes for NOA. Global gene expres-
sion analyses were performed on NOA testes, and 52 genes
were selected according to differential gene expression
between NOA subclasses with a strict statistical criterion (p
, 0.01 with Tukey’s post hoc test). Despite the fact that our
selection criteria relied only on data regarding differences in
gene expression and did not include any biological assump-
tions, many of the genes were related to spermatogenesis
based on Gene Ontology analyses (Figure 4; Table 1). 191
SNPs of 42 genes were screened, and only one gene, ART3,
showed a positive association after the two rounds of
screening. Multiple SNPs of ART3 were signiﬁcantly associ-
Figure 6. Haplotype-based Association Study of ART3
The expectation-maximization (EM) algorithm [37] was used to infer ART3
haplotype frequencies with genotyping data of five tag SNPs, ART3-
SNP1, 5, 8, 23, 25, and 28 (see Table 4). At the respective SNP sites, red
and blue boxes represent minor and major alleles, respectively.
doi:10.1371/journal.pgen.0040026.g006
Figure 7. Diplotype-Specific Differences in Serum Testosterone Levels in
NOA Patients
Three diplo-groups (code 0, 1, and 2) were defined by the number of
ART3 haplotype H1 carried. The serum testosterone levels were
significantly different among the three groups (Kruskal-Wallis; df ¼ 2, p
¼ 0.0093) by Bonferroni/Dunn post hoc test.
doi:10.1371/journal.pgen.0040026.g007
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ART3 Genetic Susceptibility Gene for NOAated with NOA, the most signiﬁcant association being
observed with ART3-SNP25 (rs6836703, nominal p ¼ 0.0025,
permutation p¼0.034; Table 4). We also detected a protective
haplotype, H1, which was the most common form and was
strongly associated with NOA (nominal p ¼ 0.000073,
corrected p ¼ 0.00080, Figure 6). In addition, diplotype
analysis showed that individuals carrying at least one
haplotype H1 showed an elevated plasma testosterone level
(Figure 7).
Functional Relevance of ART3 in the Pathogenesis of NOA
ART3 is a member of the mono-ADP-ribosyltransferase
family genes. The biological function of ART3 remains
obscure, as ART3 does not display any detectable arginine-
speciﬁc transferase activity due to lack of the active site motif
(R-S-EXE) that is essential for catalytic activity. Since differ-
entiation of stage-speciﬁc expression of ART3 in testis has
been reported, protein expression being exclusively present
in spermatocytes but absent in spermatozoa [32], a genetic
variation of ART3 might well lead to a functional defect in
the process of spermatogenesis. Haplotype H1 of ART3,
comprising all of the disease-protective alleles at the
respective SNP sites, was under-represented in the patients.
However, functional disturbance associated with haplotype
H1 is so far undetermined despite the fact that several
experiments designed to demonstrate haplotype-speciﬁc
differences in expression level have been performed. Thus,
it is possible that this haplotype represents ﬁne tuning that
maintains normal maturation of spermatocytes and improves
the efﬁciency of spermatogenesis.
In conclusion, genome-wide gene expression analyses
identiﬁed differentially expressed genes of NOA subclasses,
and ART3 was identiﬁed as a susceptibility gene underlying
NOA. This genetic study constitutes only ﬁrst-stage evidence
of association because only Japanese individuals were
included, so further replication in independent case-control
s a m p l e si sr e q u i r e dt oc o n ﬁ r mt h er o l eo ft h eART3
haplotype in genetic risk for NOA. Although further func-
tional evidence is also required, these results provide insight
into the pathoetiology of NOA as well as reproductive ﬁtness
at the molecular level, and suggest a target for therapy.
Materials and Methods
Participants. Testicular biopsy specimens for microarray analysis
were obtained from 47 Japanese patients (aged from 24 to 52 years)
with NOA and 11 (aged from 22 to 57 years) with OA, each of whom
also underwent testicular sperm extraction (TESE) for assisted
reproduction and/or diagnostic biopsy for histological examination.
The biopsies for microarray analysis and histological examination
were mainly sampled from unilateral, multiple testicular sites in the
respective patients. Each patient was ﬁrst assigned to azoospermia by
showing no ejaculated spermatozoa in a semen examination.
Subsequently, OA was deﬁned as follows: (1) motile spermatozoa
were sampled from microsurgical epididymal sperm aspiration
(MESA), or (2) a considerable number of mature spermatozoa was
sampled from TESE. NOA was tentatively deﬁned as having no
epididymal and/or testicular spermatozoa. The degree of spermato-
genic defect was histologically evaluated according to Johnsen’s score
[11]. At least three biopsies from the same individual were taken, and
the average Johnsen’s scores in the NOA and OA groups ranged from
1 to 6.5 and from 5.1 to 9, respectively. In most patients, preoperative
levels of serum follicle-stimulating hormone (FSH), leutenizing
hormone (LH), and total testosterone were measured. The infertile
male patients who visited Niigata University, Tachikawa Hospital, and
St. Mother’s Hospital received a routine semen examination accord-
ing to 1999 WHO criteria. Based on this analysis, sperm were counted
Figure 8. Immunohistochemical Analysis of ART3 Expression in Human Testes
Representative seminiferous tubules in testicular sections from normal controls (A, B), OA (C–E), and NOA patients (F–H) are shown. Arrows indicate
spermatocytes (SPC); spermatids (SPT); and Sertoli cells (SC) (B). ART3 protein was immunostained with anti-ART3 antibody; ART3-positive
spermatocytes (SPC) are noted as brown staining cells (A–E). No marked differences in testicular ART3 expression among the three ART3 diplo-groups
carrying none, one, or two copies of the protective haplotype H1were observed in OA (C–E) and NOA (F–H) patients. Magnification is 603except in (B)
(1203).
doi:10.1371/journal.pgen.0040026.g008
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ART3 Genetic Susceptibility Gene for NOAand the patients who had no ejaculated sperms were enrolled for a
case-control association study. In total, 442 patients were ascertained
to have NOA. In the current study, azoospermia patients with
varicocele, ejaculatory dysfunction, endocrinopathy, or histologically
examined OA as deﬁned above were excluded. 475 fertile men having
no speciﬁc clinical record were recruited in Niigata University. The
ethics committees of Niigata University, Tachikawa Hospital, St.
Mother’s Hospital, and Tokai University approved the study proto-
cols, and each participant gave written informed consent. Genomic
DNA was prepared from blood white cells by Dneasy (Qiagen, Tokyo,
Japan) or salivas by phenol/chloroform extraction.
To examine microdeletion of the Y chromosome in a subset of
NOA patients, PCR-based diagnostic technique was used as follows:
PCR ampliﬁcations with ﬂuorescence (FAM or HEX)-labeled primers
were performed to obtain fragments encompassing each of 13 STS
markers in and around azoospermia factor (AZF) regions of the Y
chromosome (in AZFa: SY83, SY95 and SY105; in AZFb: SY118,
G65320, SY126 and SY136; in AZFc: SY148, SY149, SY152, SY283 and
SY1291; in the heterochromatin distal to AZFc: SY166). Primer
sequences and PCR conditions are available from the authors on
request. PCR-ampliﬁed fragments were run on the ABI PRISM 3100
Genetic Analyzer (Applied Biosystems, Tokyo, Japan), and Y-
chromosome microdeletion was determined with GENESCAN soft-
ware (Applied Biosystems).
Microarray analysis of testis samples. Total RNA from testicular
biopsy was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA,
USA) and quantity and quality of the extracted RNA were examined
with 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA)
using RNA 6000 Nano LabChip (Agilent Technologies). Human Testis
Total RNA (BD Biosciences, San Jose, CA, USA), a histologically
normal testicular RNA pooled from 39 Caucasians, was used as a
common reference in two-color microarray experiments.
For ﬂuorescent cRNA synthesis, high-quality total RNA (150 ng)
was labeled with the Low RNA Input Fluorescent Linear Ampliﬁca-
tion Kit (Agilent Technologies) according to the manufacturer’s
instructions. In this procedure, cyanine 5-CTP (Cy5) and cyanine 3-
CTP (Cy3) (PerkinElmer, Boston, MA, USA) were used to generate
labeled cRNA from the extracted patient RNA and the reference
RNA, respectively. Labeled cRNAs (0.75 lg each) from one patient
and the common reference were combined and fragmented in a
hybridization mixture with the In Situ Hybridization Kit Plus (Agilent
Technologies). The mixture was hybridized for 17 hours at 658Ct o
the Agilent Human 1A(v2) Oligo Microarray, which carries 60-mer
probes to 18,716 human transcripts. After hybridization, the micro-
array was washed with SSC buffer, and then scanned in Cy3 and Cy5
channels with the Agilent DNA Microarray Scanner model G2565AA
(Agilent Technologies). Signal intensity per spot was generated from
the scanned image with Feature Extraction Software ver7.5 (Agilent
Technologies) in default setting. Spots that did not pass quality
control procedures were ﬂagged and removed for further analysis.
The Lowess (locally weighted linear regression curve ﬁt) method
was applied to normalize the ratio (Cy5/Cy3) of the signal intensities
generated in each microarray with GeneSpring GX 7.3 (Agilent
Technologies). Compared with the expression level of reference RNA,
the NOA group, with expression undergoing a 2-fold mean change or
more was extracted; the OA group comprised transcripts showing less
than 2-fold mean expression change (Figure 1A). Of the transcripts
included in both groups, only those with a statistically signiﬁcant
difference in expression between NOA and OA testes (based on
lowess-normalized natural log[Cy5/Cy3], Bonferroni’s corrected p ,
0.05) were counted as NOA-related target genes. To elucidate the
molecular subtypes of NOA, we adopted the non-negative matrix
factorization (NMF) algorithm, which has been recently introduced to
analysis of gene expression data [5,6]. For this analysis, a complete
dataset without missing values was generated from raw values of Cy5
intensities for the NOA-related target genes in the NOA samples, and
used to clarify NOA heterogeneity using three M-ﬁles (available from
the following URL; http://www.broad.mit.edu/cgi-bin/cancer/
publications/pub_paper.cgi?mode¼view&paper_id¼89) for MAT-
LAB (Mathworks, Natick, MA, USA). According to the subclassiﬁca-
tion of NOA samples, transcripts differentially expressed between
NOA subclasses were determined by one-way ANOVA, followed by
Tukey’s post hoc test in GeneSpring GX. For multiple test corrections
in this statistical analysis, we used the Benjamini-Hochberg proce-
dure [33] of controlling the false discovery rate (FDR) at the level of
0.05 or 0.01. To analyze which categories of Gene Ontology were
statistically overrepresented among the gene lists obtained, we used
GO Browser, an optional tool in GeneSpring GX, where the statistical
signiﬁcance was determined by Fisher’s exact test. The microarray
data reported in this paper have been deposited in the Gene
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) data-
base, and are accessible through GEO Series accession number
GSE9210.
Quantitative real-time RT-PCR analysis for validation of between-
subclass differences in gene expression. Quantitative real-time RT-
PCR analysis was used to verify the microarray data on 53 transcripts
representing differential expressions between NOA subclasses with
high signiﬁcance (p , 0.01). Among 53 transcripts, VCX
(NM_013452), VCX2 (NM_016378), and VCX3A (NM_016379)
were examined as a single transcript because sequence homologies
between the three transcripts prevented development of appropriate
assays for discrimination. Testicular total RNA (1 lg) subjected to
microarray analysis was used as a template in ﬁrst-strand cDNA
synthesis with SuperScript III First-Strand Synthesis System (Invi-
trogen). Each single-stranded cDNA was diluted one-tenth for a
subsequent real-time RT-PCR using SYBR Premix Ex Taq (Perfect Real
Time) (TAKARA BIO, Otsu, Japan) on the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems) according to the
manufacturer’s instructions. The PCR primers for 43 transcripts
showing between-subclass differences with high signiﬁcance and
GAPDH were designed and synthesized by TAKARA BIO Inc., or
QIAGEN GmbH (as the QuantiTect Primer Assay). In the real-time
RT-PCR analysis for the nine remaining transcripts, we used TaqMan
Gene Expression Assays (Applied Biosystems) with TaqMan Universal
PCR Master Mix (No AmpErase UNG version) according to the
manufacturer’s instructions (Applied Biosystems). The detailed
information on the primer sequences used and/or the assay system
selected are summarized in Table S3. A relative quantiﬁcation
method [34] was used to measure the amounts of the respective
genes in NOA testes, normalized to GAPDH as an endogenous
control, and relative to Human Testis Total RNA (BD Biosciences) as
a reference RNA. Statistical signiﬁcance between NOA subclasses was
determined by Kruskal-Wallis test, followed by multiple comparisons;
p , 0.05 was considered signiﬁcant.
SNP selection of candidate genes for NOA and genotyping. Based
on gene expression data of NOA testes, we selected 52 genes
(encoding 53 transcripts) as candidates for genetic susceptibilities
underlying NOA. SNPs of the candidate genes with minor allele
frequency (MAF) . 0.05 were obtained from the NCBI dbSNP
database (http://www.ncbi.nlm.nih.gov/SNP/), and applied to an initial
screening. Of the 52 candidate genes, 10 genes (CTAG1B,
LOC158812, LOC255313, MAGEA2, PEPP-2, TSPY1, TSPY2, VCX3A,
VCY, and XAGE1) were excluded from the initial screening because
gene-based SNPs with MAF . 0.05 were not found in the public SNP
database. A total of 191 SNPs of 42 genes were genotyped in the
screening with TaqMan SNP Genotyping Assays on the ABI PRISM
7900HT Sequence Detection System (Applied Biosystems). 190 NOA
patients (cases) and 190 fertile men (controls) were genotyped in the
ﬁrst round screening. For genes with at least one SNP showing a
discrepancy in MAF of 5% or greater between cases and controls, the
sample size was increased to 380 cases and 380 controls in the second
round.
After two rounds of initial screening, additional SNPs of ART3
were selected from dbSNP or identiﬁed by direct sequencing of all 12
exons of the gene (Ensemble transcript ID ENST00000355810) and
splice acceptor and donor sites in the intron using the genomic DNAs
from 95 infertile patients as PCR templates. A total of 38 SNPs of
ART3 were ﬁnally genotyped on 442 cases and 475 controls by
TaqMan SNP Genotyping Assays or by direct sequencing with BigDye
Terminators v3.1 Cycle Sequencing Kit (Applied Biosystems) on ABI
PRISM 3700 DNA analyzer.
Statistical analyses in association study. Pairwise linkage disequi-
librium (LD), using the standard deﬁnition of D’ and r
2 [35,36], was
measured with SNPAlyze v5.0 software (DYNACOM, Mobara, Japan).
To construct ART3 haplotypes in phase-unknown samples, tag SNPs
of ART3 were selected with Tagger software [25], incorporated in the
Haploview. The expectation-maximization (EM) algorithm [37] and
PHASE version 2.1.1 [26,27] was used to infer haplotype frequencies
and individual diplotypes for ART3. Differences in allelic and
haplotype frequencies were evaluated using a case-control design
with the chi-square test. For an adjustment of multiple testing, we
applied a permutation method with Haploview version 3.32 software,
or Bonferroni’s method to determine corrected p-values.
To investigate association of the ART3 diplotype with clinical
phenotypes such as serum hormone levels, differences among the
three categories (code 0, 1, and 2), deﬁned by the number of the most
signiﬁcant haplotype, were statistically examined by Kruskal-Wallis
test, followed by Bonferroni/Dunn post hoc test (StatView version 5.0,
SAS Institute, Cary, NC, USA).
Immunohistochemistry. To examine cellular localization of ART3
PLoS Genetics | www.plosgenetics.org February 2008 | Volume 4 | Issue 2 | e26 0012
ART3 Genetic Susceptibility Gene for NOAprotein in azoospermic testes, testicular biopsy specimens from 15
OA and 12 NOA patients were subjected to immunohistochemistry.
Four postmortem testicular tissues of accidental sudden-deaths were
used as normal controls. The testicular tissues were ﬁxed in 10%
buffered formalin and embedded in parafﬁn. Cryosections (3 lm
thickness) were pre-incubated with the Histoﬁne Antigen-Retrieval
Solution (1:10 dilution; Nichirei Bioscience, Tokyo, Japan) for 10
minutes at 95 8C. The sections were then incubated with primary
ART3 antibody (1:4,000; Abnova, Taipei, Taiwan), then with IgG2b
isotype (1:4,000; MBL International, Woburn, USA) for 60 minutes at
room temperature. After washing with PBS, the sections were
incubated with the Histoﬁne Simple Stain Max-PO (Multi) (1:5
dilution; Nichirei Bioscience) for 30 minutes at room temperature,
and then reacted with DAB (Nichirei Bioscience) for 10 minutes at
room temperature. Haematoxylin was used for counterstaining.
Supporting Information
Figure S1. Statistical Analysis Reveals Transcripts Differentially
Expressed among Three NOA Subclasses
Venn diagram summaries show the number of transcripts differ-
entially expressed with signiﬁcance by Tukey’s post hoc test in each
comparison (see Table S1)
Found at doi:10.1371/journal.pgen.0040026.sg001 (694 KB EPS).
Figure S2. Comparisons of Expression Levels of 149 Transcripts
Expressed Differentially between Three NOA Subclasses in Micro-
array Analysis (Part I)
Natural log-transformed normalized ratios of NOA to testis reference
(y-axes) were subjected to statistical analysis, as described in Materials
and Methods. Each column represents mean 6 standard error of the
mean. The 53 transcripts with highly signiﬁcant (p , 0.01, Tukey test)
differences between the three NOA subclasses are shown in red.
Found at doi:10.1371/journal.pgen.0040026.sg002 (773 KB EPS).
Figure S3. Comparisons of Expression Levels of 149 Transcripts
Expressed Differentially between Three NOA Subclasses in Micro-
array Analysis (Part II)
Natural log-transformed normalized ratios of NOA to testis reference
(y-axes) were subjected to statistical analysis, as described in Materials
and Methods. Each column represents mean 6 standard error of the
mean. The 53 transcripts with highly signiﬁcant (p , 0.01, Tukey test)
differences between the three NOA subclasses are shown in red.
Found at doi:10.1371/journal.pgen.0040026.sg003 (798 KB EPS).
Figure S4. Comparisons of Expression Levels of 149 Transcripts
Expressed Differentially between Three NOA Subclasses in Micro-
array Analysis (Part III)
Natural log-transformed normalized ratios of NOA to testis reference
(y-axes) were subjected to statistical analysis, as described in Materials
and Methods. Each column represents mean 6 standard error of the
mean. The 53 transcripts with highly signiﬁcant (p , 0.01, Tukey test)
differences between the three NOA subclasses are shown in red.
Found at doi:10.1371/journal.pgen.0040026.sg004 (822 KB EPS).
Figure S5. Correlations of Testicular Gene Expression Evaluated by
Microarray and Quantitative Real-Time RT-PCR Analyses
Expression levels of 51 transcripts with highly signiﬁcant (p , 0.01)
differences in expression among the three NOA subclasses were
quantiﬁed by real-time RT-PCR method as described in Material and
Methods. Squares of correlation coefﬁcients (R
2) for the respective
transcripts were calculated between normalized expression ratios of
NOA to testis reference in microarray data (x-axes) and the
corresponding ratios obtained by real-time RT-PCR analysis (y-axes)
Found at doi:10.1371/journal.pgen.0040026.sg005 (1.7 MB EPS).
Table S1. 149 Transcripts Representing Statistically Signiﬁcant (p ,
0.05) Differences in Testicular Expression between Three NOA
Subclasses
Found at doi:10.1371/journal.pgen.0040026.st001 (68 KB XLS).
Table S2. Comparison of Minor Allele Frequencies (MAFs) at 191
SNPs of 42 Genes between 190 Infertile Patients and 190 Fertile Males
(First Round of Initial Screening)
Found at doi:10.1371/journal.pgen.0040026.st002 (415 KB DOC).
Table S3. Quantitative Real-time RT-PCR Assays for 51 Transcripts
Representing Highly Signiﬁcant Differences between NOA Subclasses
Found at doi:10.1371/journal.pgen.0040026.sg003 (30 KB XLS).
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